Resbiotic does not make alternatives to GLP-1 drugs
Mental-health screening of this specificity is uncommon in public GLP-1 shopping funnels most either skip mental health entirely or fold it into a vague do you have any mental health conditions free-text field
The three scenarios for compounded semaglutide access post-shortage When the FDA removes semaglutide from the shortage list, compounding pharmacies face three possible paths forward: Scenario 1: Full cessation
Several clinical trials implemented a combination of semaglutide treatments with sulfonylurea, sitagliptin, basal insulin, metformin, or other antidiabetic drugs (Table 3)
Compounded semaglutide and tirzepatide cost a fraction of brand-name Ozempic, Wegovy, Mounjaro, or Zepbound for two reasons: no brand-name pricing markup, and lower distribution overhead through telehealth
Additionally, 93% reported an improved quality of life, and 78% felt equipped to sustain results without ongoing medication